-
FDA approves COVID-19 antiviral Xocova as PEP. But will it be accessible?
Shionogi, the Japanese company that makes Xocova (ensitrelvir), said the post-exposure prophylaxis drug will be available in mid-July in the U.S. and will have a list price of $1,400. But its impact will hinge on how easily people can access it, experts say. Read more…
Recent articles
Get the latest Long COVID news and commentary
Processing…
Success! You're on the list.
Whoops! There was an error and we couldn't process your subscription. Please reload the page and try again.
Check out our weekly podcast, Still Here
Spotify
Apple Podcasts
PocketCasts
iHeartRadio
RSS
Policy & Advocacy
-
“Millions Missing” protest at the Capitol demands myalgic encephalomyelitis funding, social support
-
Minnesota House budget proposes eliminating state Long COVID program
-
“Long COVID Mode”: Seeing the crisis through games
-
$11 billion CDC funding cuts may decimate Long COVID response in several states
-
An international emergency task force is urgently needed for Severe Long COVID and ME crisis cases
-
The history of ME deserves a late-night spotlight. That’s why we started the #JohnVsJonVsME campaign.
Science
Covid-19
Health
-
Nicotine patches help relieve symptoms in some people with Long COVID. Can the science behind it lead to future therapies?
-
Despite the ongoing pandemic, some companies are banning employees from masking
-
Getting diagnosed with hypermobility can help some people with Long COVID. Upcoming guidelines may make it easier.
-
Long COVID is not FND, but some patients are getting diagnosed with it. Here’s what to do if it happens to you.
-
Violet Affleck advocates for children with Long COVID, masks, and clean indoor air at United Nations event
-
Epidemiologist Caitlin Rivers shares advice for interpreting COVID-19 and other infectious disease data
